Landing strip and surrounding landscape as seen from the approaching plane.

Plane landing

Titratable Control of blood pressure reduction with CLEVIPREX^® (clevidipine)

CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in case of acute severe hypertension. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.¹
How It Works

Titratable Control of blood pressure reduction with CLEVIPREX^® (clevidipine)

Plane landing

CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in case of acute severe hypertension. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.¹
How It Works

BP reduction in a range of patients and clinical settings^1-5

Proven efficacy in:

Perioperative hypertension
Acute severe hypertension
Intracerebral hemorrhage (ICH)

Explore 4 clinical studies

Established safety profile in multiple clinical trials^2,3,6

CLEVIPREX demonstrated safety vs:

Nicardipine in postoperative hypertension
Sodium nitroprusside and nitroglycerin in perioperative hypertension
Placebo in perioperative hypertension

See Comparative Safety Data

Rapidly lowers arterial BP with fast onset and offset¹

Titratable, fast onset of action (within 2 minutes of initiation)
~1-minute half-life
Metabolized independent of renal or hepatic function

See Pharmacology Data

Non–weight-based dosing¹

CLEVIPREX dosing is also:

A low infusion volume¹
Available as ready-to-use 50- and 100-mL vials¹

Get More Dosing Info

Low-volume dosing option¹

Excessive fluid intake may lead to adverse outcomes in critically ill patients^7,8:

Consider the results of the ECLIPSE trials
See how infusion volumes varied between hypertensive agents in the postoperative setting

CLEVIPREX has not been studied or proven to impact fluid overload.

Learn More About ECLIPSE

Access resources for CLEVIPREX

Watch KOL videos, download a summary of the American Heart Association/American Stroke Association (AHA/ASA) Guidelines, and more.

Go to resources

Important Safety Information

CLEVIPREX^® (clevidipine) Injectable Emulsion is contraindicated in patients with:

Allergies to soybeans, soy products, eggs, or egg products;
Defective lipid metabolism seen in conditions such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and
Severe aortic stenosis.

CLEVIPREX^® is intended for intravenous use. Use aseptic technique and discard any unused product within 12 hours of stopper puncture.

Hypotension and reflex tachycardia are potential consequences of rapid upward titration of CLEVIPREX^®. If either occurs, decrease the dose of CLEVIPREX^®. There is limited experience with short-duration therapy with beta-blockers as a treatment for CLEVIPREX^®-induced tachycardia. Beta-blocker use for this purpose is not recommended.

CLEVIPREX^® contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism.

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.

CLEVIPREX^® is not a beta-blocker, does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.

Patients who receive prolonged CLEVIPREX^® infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

There is no information to guide use of CLEVIPREX^® in treating hypertension associated with pheochromocytoma.

Most common adverse reactions for CLEVIPREX^® (>2%) are headache, nausea, and vomiting.

Indication

CLEVIPREX^® (clevidipine) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable.

Please see Full Prescribing Information.

References: 1. CLEVIPREX® (clevidipine) Prescribing Information. 2021. 2. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105(4):918-925. 3. Singla N, Warltier DC, Gandhi SD, et al; ESCAPE-2 Study Group. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59-67. 4. Pollack CV, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Peacock WF. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):329-338. 5. Graffagnino C, Bergese S, Love J, et al. Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial. Cerebrovasc Dis. 2013;36(3):173-180. 6. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110-1121. 7. Child DL, Cao Z, Seiberlich LE, et al. The costs of fluid overload in the adult intensive care unit: is a small-volume infusion model a proactive solution? Clinicoecon Outcomes Res. 2014;7:1-8. 8. O’Connor ME, Prowle JR. Fluid overload. Crit Care Clin. 2015;31(4):803-821.